Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Sees Significant Drop in Short Interest

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) saw a significant drop in short interest during the month of August. As of August 14th, there was short interest totaling 8,194 shares, a drop of 77.9% from the July 30th total of 37,127 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average trading volume of 64,625 shares, the days-to-cover ratio is currently 0.1 days.

Regentis Biomaterials Stock Performance

Shares of NYSEAMERICAN:RGNT opened at $2.09 on Wednesday. The business has a fifty day moving average price of $2.77 and a two-hundred day moving average price of $2.97. Regentis Biomaterials has a 1 year low of $1.23 and a 1 year high of $15.50.

Hedge Funds Weigh In On Regentis Biomaterials

A hedge fund recently bought a new position in Regentis Biomaterials stock. AIGH Capital Management LLC purchased a new position in shares of Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned 5.79% of Regentis Biomaterials as of its most recent filing with the SEC.

About Regentis Biomaterials

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.